Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR.

Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR.

Item
http://www.wikidata.org/entity/Q34250227
Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expressionRisk of hormone escape in a human prostate cancer model depends on therapy modalities and can be reduced by tyrosine kinase inhibitorsSupraphysiological androgen levels induce cellular senescence in human prostate cancer cells through the Src-Akt pathway.A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer.The Coffey Lecture: steroidogenic enzyme inhibitors and hormone dependent cancerInvestigating prostate cancer tumour-stroma interactions: clinical and biological insights from an evolutionary gameEmerging targeted therapies for castration-resistant prostate cancer.Galeterone and VNPT55 induce proteasomal degradation of AR/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo.Enhanced inhibition of prostate cancer xenograft tumor growth by combining quercetin and green tea.Role of signaling transduction pathways in development of castration-resistant prostate cancer.Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.In vivo quantitative phosphoproteomic profiling identifies novel regulators of castration-resistant prostate cancer growth.Identification of ML-9 as a lysosomotropic agent targeting autophagy and cell death.mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancerSynergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer.Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer.The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancer.
P2860

Prolonging hormone sensitivity in prostate cancer xenografts through dual inhibition of AR and mTOR.

Item
http://www.wikidata.org/entity/Q34250227
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Prolonging hormone sensitivity ...... ual inhibition of AR and mTOR.
@ast
Prolonging hormone sensitivity ...... ual inhibition of AR and mTOR.
@en
Prolonging hormone sensitivity ...... ual inhibition of AR and mTOR.
@nl
type
label
Prolonging hormone sensitivity ...... ual inhibition of AR and mTOR.
@ast
Prolonging hormone sensitivity ...... ual inhibition of AR and mTOR.
@en
Prolonging hormone sensitivity ...... ual inhibition of AR and mTOR.
@nl
prefLabel
Prolonging hormone sensitivity ...... ual inhibition of AR and mTOR.
@ast
Prolonging hormone sensitivity ...... ual inhibition of AR and mTOR.
@en
Prolonging hormone sensitivity ...... ual inhibition of AR and mTOR.
@nl
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P6179
P698
P921
P932
P356
P1433
P1476
Prolonging hormone sensitivity ...... dual inhibition of AR and mTOR
@en
P2093
P2860
P2888
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P6179
P698
P921
P932